Hub : Traits :

Forced expiratory volume in 1-second (FEV1), predicted

621 significantly associated models · 166 unique genes.

Significant Loci

# chr p0 p1 # assoc genes # joint genes best TWAS P best SNP P cond SNP P % var exp joint genes
1 1 16273995 18074702 7 1 7.5e-10 8.8e-12 2.3e-03 80 MST1L
2 1 40748755 42406344 2 1 5.4e-10 2.3e-11 2.5e-03 80 CTPS1
3 1 50735395 52135979 1 1 5.1e-09 9.1e-10 2.7e-02 87 CDKN2C
4 1 149672809 150515021 3 1 1.6e-09 6.2e-16 6.7e-08 55 RP11-196G18.22
5 1 183325796 184739300 1 1 5.1e-16 7.2e-16 6.7e-02 95 TSEN15
6 1 223846564 225265424 1 1 8.4e-08 1.9e-07 1.0e+00 100 CNIH4
7 1 227222963 228614123 1 1 1.9e-07 2.2e-07 1.8e-01 94 JMJD4
8 2 24348096 25837917 2 1 7.9e-09 2.1e-10 6.5e-06 50 ADCY3
9 2 32483593 34319972 1 1 3.9e-07 6.7e-08 6.0e-03 74 LTBP1
10 2 55401562 56843605 1 1 9.3e-11 1.8e-13 2.2e-04 75 EFEMP1
11 2 168949234 170419444 1 2 1.2e-12 6.4e-11 1.0e+00 100 NOSTRIN
12 2 218827778 220226393 1 1 5.4e-08 5.1e-06 1.1e-01 87 BCS1L
13 2 231913056 233900089 3 2 9.8e-11 3.0e-08 3.4e-01 97 DIS3L2 PDE6D
14 3 49615624 50998816 1 1 9.3e-08 2.5e-07 6.8e-01 99 SEMA3B-AS1
15 3 140350567 142017527 2 1 5.1e-30 6.1e-30 1.0e+00 100 ZBTB38
16 4 17104059 18533844 2 1 8.2e-27 6.6e-28 9.1e-06 84 DCAF16
17 4 144758204 146788825 4 2 1.2e-14 7.0e-23 4.9e-12 51 OTUD4 RP11-361D14.2
18 5 130830617 132693330 8 1 5.3e-12 3.0e-09 1.0e+00 100 P4HA2
19 5 176040488 177260129 1 1 1.0e-12 3.4e-12 7.2e-03 85 RAB24
20 5 178968049 180374523 1 1 4.1e-08 8.4e-10 1.9e-03 74 MAPK9
21 6 33745071 36412658 8 10 3.2e-17 1.5e-19 NaN NaN C6orf106 C6orf81 DEF6 PACSIN1 RPL10A ZNF76
22 6 83082766 84576263 1 1 3.7e-07 7.8e-06 2.6e-01 94 DOPEY1
23 6 104478130 106230491 2 1 1.0e-10 1.2e-17 2.0e-08 57 LIN28B
24 6 125970401 127355237 1 1 8.9e-11 4.7e-12 1.6e-02 88 CENPW
25 6 129638583 131163098 2 1 2.4e-17 7.0e-16 1.0e+00 100 RP11-73O6.3
26 6 141924760 143855272 2 1 4.7e-17 1.8e-18 1.0e+00 100 GPR126
27 7 2032803 5003373 3 2 2.1e-15 2.5e-15 1.0e+00 100 GNA12 SDK1
28 7 91492103 93160671 2 1 4.2e-12 3.6e-14 8.4e-05 73 CDK6
29 8 123101743 124679448 1 1 3.2e-07 2.4e-06 1.0e+00 100 ZHX2
30 8 130062993 131498180 1 1 3.4e-09 1.2e-10 9.7e-03 84 GSDMC
31 9 97573117 98969746 1 1 1.2e-09 1.2e-14 1.6e-11 24 RP11-435O5.5
32 9 138628816 140071683 2 1 4.0e-08 1.4e-07 8.1e-01 100 SEC16A
33 10 4268118 5844628 2 1 2.8e-09 7.2e-08 1.0e+00 100 AKR1C3
34 10 103527782 105282664 8 1 6.4e-11 2.7e-08 2.8e-01 96 TMEM180
35 11 66468469 67856510 1 1 2.3e-17 3.0e-17 1.0e+00 100 RAD9A
36 12 191619 1190134 1 1 1.8e-07 1.5e-07 9.6e-04 60 KDM5A
37 12 27414205 29432481 3 1 6.0e-13 1.4e-13 2.0e-02 90 CCDC91
38 12 55677395 57452308 7 1 8.6e-08 1.2e-07 2.7e-01 96 RP11-977G19.11
39 12 93165619 94589220 1 1 3.3e-07 3.5e-15 6.8e-10 39 MRPL42
40 13 49557805 51982196 3 3 6.2e-08 1.3e-12 3.0e-06 57 DLEU1 DLEU2 EBPL
41 14 91831899 93223990 1 1 1.1e-07 1.7e-07 1.0e+00 100 RP11-529H20.5
42 15 73524629 74915888 1 1 1.6e-07 2.6e-06 2.4e-04 39 LOXL1-AS1
43 15 84151637 85895721 13 1 7.6e-14 2.4e-15 1.0e-06 62 AC103965.1
44 15 99816860 101209341 1 1 1.5e-08 5.7e-10 7.1e-08 24 CTD-3076O17.1
45 17 6652789 8112253 3 1 3.0e-08 5.1e-08 4.3e-02 86 CHRNB1
46 17 17484654 18914778 1 1 1.9e-07 6.0e-07 6.3e-01 99 TOP3A
47 17 28398977 30034689 2 2 2.4e-11 4.2e-18 3.2e-06 71 CRLF3 RP11-848P1.7
48 17 60916262 62694738 9 2 9.8e-13 9.8e-12 3.6e-01 98 CD79B DDX42
49 18 20082830 21863589 4 2 7.0e-13 2.2e-24 1.0e-11 55 C18orf8 NPC1
50 18 45873080 47686517 1 1 1.0e-07 3.1e-07 8.7e-02 89 DYM
51 20 31382860 35512648 33 11 1.2e-24 3.7e-30 NaN NaN E2F1 FAM83C GDF5 GGT7 MAP1LC3A MMP24 NCOA6 PHF20 TP53INP2 UQCC UQCC1

Pleiotropic Associations

Trait chisq ratio # genes+ # genes++ % genes++ corr corr P genes
Crohns Disease (2017) 1.81 4 3 9.1 0.79 2.1e-01 ADCY3 P4HA2 SEC16A ZBTB38
Irritable Bowel Disease (IBD) 1.88 6 2 6.1 0.16 7.6e-01 ADCY3 CENPW DCAF16 GNA12 P4HA2 SEC16A
Ulcerative Colitis (UC) 1.97 4 2 6.1 -0.10 9.0e-01 FAM83C GNA12 MMP24 SEC16A
Reaction Time 1.34 1 0 0.0 0.00 1.0e+00 TMEM180
Verbal and Numeric Reasoning (VNR) 1.48 2 1 3.0 0.00 1.0e+00 CENPW DCAF16
Breast Cancer 2.20 6 5 15.2 0.54 2.7e-01 ADCY3 P4HA2 RP11-196G18.22 RP11-73O6.3 RP11-848P1.7 ZBTB38
Ovarian Cancer 1.21 1 0 0.0 0.00 1.0e+00 CRLF3
Prostate Cancer 1.95 1 0 0.0 0.00 1.0e+00 TMEM180
Body Mass Index (BMI) (2010) 1.68 1 0 0.0 0.00 1.0e+00 ADCY3
Coronary Artery Disease (CAD) 2.20 1 0 0.0 0.00 1.0e+00 C6orf106
Crohns Disease (2012) 1.33 1 1 3.0 0.00 1.0e+00 P4HA2
Fasting Glucose 1.57 1 1 3.0 0.00 1.0e+00 NOSTRIN
HDL Cholesterol 2.32 3 1 3.0 0.96 9.8e-03 C6orf106 MAP1LC3A NCOA6
LDL Cholesterol 2.04 1 1 3.0 0.00 1.0e+00 C6orf106
Lupus 1.64 2 0 0.0 0.00 1.0e+00 DEF6 ZNF76
Rheumatoid Arthritis 1.48 1 0 0.0 0.00 1.0e+00 CDK6
Schizophrenia 1.37 3 2 6.1 0.00 1.0e+00 AC103965.1 DOPEY1 LIN28B
Triglycerides 1.02 1 0 0.0 0.00 1.0e+00 MAP1LC3A
Ulcerative Colitis 2.19 3 2 6.1 0.00 1.0e+00 GNA12 MMP24 SEC16A
Blood Eosinophil Count 2.28 14 7 21.2 0.43 1.1e-01 AC103965.1 CDK6 CRLF3 DLEU2 GNA12 NOSTRIN P4HA2 PACSIN1 RAB24 RP11-73O6.3 RPL10A SEC16A SEMA3B-AS1 ZNF76
Blood Platelet Count 2.15 21 15 45.5 0.85 3.1e-07 AC103965.1 BCS1L C18orf8 C6orf106 CDK6 CHRNB1 CRLF3 CTPS1 DCAF16 DDX42 DYM E2F1 GNA12 NPC1 OTUD4 P4HA2 PACSIN1 RP11-361D14.2 RP11-848P1.7 TMEM180 ZHX2
Blood Red Count 1.44 17 9 27.3 0.02 9.3e-01 AC103965.1 BCS1L C6orf106 CD79B CENPW CNIH4 E2F1 GPR126 MST1L PHF20 RAD9A RP11-435O5.5 RP11-73O6.3 RP11-977G19.11 SEC16A SEMA3B-AS1 ZBTB38
Blood White Count 2.78 24 17 51.5 0.35 8.7e-02 BCS1L C18orf8 C6orf81 CDK6 CENPW CNIH4 DCAF16 DDX42 DEF6 DLEU1 EBPL GNA12 NCOA6 NOSTRIN P4HA2 PACSIN1 RP11-435O5.5 RP11-73O6.3 RPL10A SEC16A TMEM180 TP53INP2 ZHX2 ZNF76
Heel T-Score 3.93 40 32 97.0 0.45 3.5e-03 ADCY3 C18orf8 C6orf81 CCDC91 CDK6 CDKN2C CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DIS3L2 DLEU1 DLEU2 DOPEY1 DYM E2F1 EBPL FAM83C GGT7 GNA12 GPR126 GSDMC JMJD4 LIN28B MAP1LC3A MST1L NCOA6 PDE6D RAB24 RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RPL10A UQCC1 ZBTB38 ZNF76
BMI 2.44 16 10 30.3 -0.09 7.2e-01 ADCY3 C18orf8 C6orf106 CHRNB1 DCAF16 DDX42 DYM GPR126 LOXL1-AS1 LTBP1 MST1L NCOA6 OTUD4 PACSIN1 RAB24 RP11-73O6.3
Height 26.69 73 73 221.2 -0.97 3.2e-51 AC103965.1 ADCY3 AKR1C3 BCS1L C18orf8 C6orf106 C6orf81 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DOPEY1 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LIN28B LOXL1-AS1 LTBP1 MAP1LC3A MAPK9 MMP24 MRPL42 MST1L NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A SEMA3B-AS1 TMEM180 TOP3A TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Waist Hip Ratio (WHR) 3.76 26 17 51.5 0.35 7.1e-02 AC103965.1 ADCY3 AKR1C3 C6orf106 CD79B CENPW DIS3L2 DLEU2 DYM EBPL FAM83C GDF5 GGT7 MST1L NCOA6 OTUD4 PHF20 RAB24 RAD9A RP11-361D14.2 RP11-529H20.5 RP11-73O6.3 TOP3A UQCC UQCC1 ZBTB38
Systolic Blood Pressure 1.64 11 4 12.1 0.04 9.1e-01 ADCY3 CDK6 DCAF16 EFEMP1 GDF5 GPR126 JMJD4 RPL10A SEMA3B-AS1 UQCC ZHX2
Smoking Status 1.60 3 0 0.0 0.00 1.0e+00 C6orf106 MAP1LC3A TMEM180
Allergy or Eczema 2.54 7 4 12.1 0.14 7.0e-01 C6orf106 GNA12 MAP1LC3A P4HA2 PACSIN1 TMEM180 ZBTB38
Cardiovascular Disease 1.51 6 3 9.1 0.42 4.0e-01 C18orf8 C6orf106 CDK6 CRLF3 DCAF16 ZNF76
Hypothyroidism (self reported) 0.95 1 0 0.0 0.00 1.0e+00 DLEU1
Respiratory disease 1.83 3 2 6.1 0.00 1.0e+00 DEF6 P4HA2 ZNF76
Type 2 Diabetes (T2D) 1.44 1 0 0.0 0.00 1.0e+00 CENPW
Lung FEV1/FVC ratio 7.31 29 21 63.6 -0.16 3.8e-01 AC103965.1 ADCY3 C6orf106 C6orf81 CDKN2C CENPW DEF6 EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 LOXL1-AS1 MAP1LC3A MST1L NCOA6 OTUD4 P4HA2 PHF20 RP11-361D14.2 RP11-435O5.5 RPL10A TOP3A TP53INP2 UQCC UQCC1 ZBTB38 ZNF76
Lung FVC 5.32 39 27 81.8 0.36 1.9e-02 C18orf8 C6orf106 CCDC91 CD79B CENPW CHRNB1 CNIH4 CRLF3 DCAF16 DDX42 EBPL EFEMP1 FAM83C GDF5 GGT7 LIN28B LOXL1-AS1 LTBP1 MAP1LC3A MMP24 MST1L NCOA6 NPC1 P4HA2 PDE6D PHF20 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A SEMA3B-AS1 UQCC UQCC1 ZBTB38 ZNF76
Neuroticism 1.29 3 0 0.0 0.00 1.0e+00 CENPW LIN28B TMEM180
Chronotype (morning person) 1.19 3 1 3.0 0.00 1.0e+00 ADCY3 SEC16A SEMA3B-AS1
Hair Pigment 3.28 19 13 39.4 0.50 2.3e-02 ADCY3 C6orf106 CENPW E2F1 FAM83C GDF5 GGT7 MAP1LC3A MMP24 NCOA6 PHF20 RP11-196G18.22 RP11-73O6.3 SEC16A TP53INP2 UQCC UQCC1 ZBTB38 ZNF76
Tanning 6.07 12 11 33.3 -0.85 4.5e-04 ADCY3 E2F1 FAM83C GDF5 GGT7 MAP1LC3A MMP24 NCOA6 PHF20 TP53INP2 UQCC UQCC1
Hand grip strength (left) 7.73 29 20 60.6 0.96 5.9e-17 ADCY3 BCS1L C6orf106 CD79B CENPW DCAF16 DEF6 DLEU1 DYM FAM83C GDF5 GGT7 JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MMP24 NCOA6 NPC1 P4HA2 PHF20 RAD9A RP11-73O6.3 TMEM180 TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Number of treatments/medications taken 1.60 3 0 0.0 0.00 1.0e+00 C6orf106 DCAF16 LIN28B
Relative age of first facial hair 3.11 8 4 12.1 -0.08 8.2e-01 C18orf8 C6orf106 GDF5 LIN28B NCOA6 SEMA3B-AS1 UQCC ZBTB38
Systolic blood pressure, automated reading 1.78 7 1 3.0 -0.77 4.4e-02 ADCY3 CDK6 DCAF16 DLEU1 EFEMP1 RPL10A ZHX2
Pack years adult smoking proportion 1.37 1 0 0.0 0.00 1.0e+00 C18orf8
Impedance of leg (right) 3.73 28 19 57.6 -0.21 2.6e-01 AC103965.1 ADCY3 BCS1L C6orf106 CD79B CDK6 CTD-3076O17.1 DLEU1 E2F1 FAM83C GDF5 LIN28B LTBP1 MAP1LC3A MMP24 MST1L NCOA6 OTUD4 PACSIN1 PHF20 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SEMA3B-AS1 TOP3A UQCC UQCC1
Leg fat-free mass (left) 14.93 61 47 142.4 0.95 3.1e-34 AKR1C3 C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LIN28B LOXL1-AS1 MAP1LC3A MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Trunk fat percentage 3.05 16 10 30.3 0.70 1.3e-03 AC103965.1 ADCY3 C18orf8 C6orf106 CD79B CENPW CTD-3076O17.1 EFEMP1 GNA12 OTUD4 PACSIN1 RAD9A RP11-196G18.22 RPL10A TP53INP2 ZBTB38
Hand grip strength (right) 9.00 35 22 66.7 0.96 1.1e-19 ADCY3 AKR1C3 BCS1L C6orf106 CD79B CTPS1 DCAF16 DDX42 DEF6 DLEU1 DYM E2F1 FAM83C GDF5 GGT7 JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MMP24 NCOA6 NOSTRIN NPC1 P4HA2 PACSIN1 PHF20 RAD9A RP11-73O6.3 TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZNF76
Maternal smoking around birth 1.31 1 0 0.0 0.00 1.0e+00 DCAF16
Frequency of unenthusiasm / disinterest in last 2 weeks 1.14 1 0 0.0 0.00 1.0e+00 LOXL1-AS1
Relative age voice broke 2.70 4 1 3.0 -0.27 7.3e-01 GDF5 LIN28B NCOA6 UQCC
Age when periods started (menarche) 3.87 5 3 9.1 0.49 4.0e-01 ADCY3 CENPW DOPEY1 LIN28B SEMA3B-AS1
Heel bone mineral density (BMD) T-score, automated (left) 2.36 8 2 6.1 -0.64 8.8e-02 CDK6 CTPS1 DLEU2 DOPEY1 EBPL LIN28B NCOA6 RP11-435O5.5
High blood pressure 1.32 3 1 3.0 0.00 1.0e+00 C6orf106 DCAF16 P4HA2
Hayfever, allergic rhinitis or eczema 2.28 5 2 6.1 -0.43 2.8e-01 C6orf106 P4HA2 PACSIN1 TMEM180 ZBTB38
Multivitamins +/- minerals 1.44 1 0 0.0 0.00 1.0e+00 NCOA6
Sitting height 23.02 66 61 184.8 0.93 9.3e-31 AC103965.1 ADCY3 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTD-3076O17.1 CTPS1 DCAF16 DDX42 DIS3L2 DLEU1 DLEU2 DOPEY1 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 LTBP1 MAP1LC3A MAPK9 MMP24 MRPL42 MST1L NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
High blood pressure (mother) 1.41 1 0 0.0 0.00 1.0e+00 C18orf8
Body mass index (BMI) 2.13 11 3 9.1 0.19 5.2e-01 ADCY3 C18orf8 C6orf106 DCAF16 DDX42 LOXL1-AS1 MST1L NCOA6 OTUD4 PACSIN1 RP11-73O6.3
Impedance of leg (left) 3.64 30 20 60.6 -0.22 2.2e-01 AC103965.1 ADCY3 BCS1L C6orf106 CD79B CDK6 CTD-3076O17.1 DLEU1 E2F1 FAM83C GDF5 GGT7 GPR126 LIN28B LTBP1 MAP1LC3A MMP24 MST1L NCOA6 OTUD4 PACSIN1 PHF20 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SEMA3B-AS1 TOP3A UQCC UQCC1
Leg predicted mass (left) 14.89 61 47 142.4 0.95 3.0e-34 AKR1C3 C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LIN28B LOXL1-AS1 MAP1LC3A MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Trunk fat mass 5.99 30 25 75.8 0.91 1.3e-13 AC103965.1 ADCY3 C18orf8 C6orf106 CDK6 CTD-3076O17.1 E2F1 EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 LIN28B NCOA6 NPC1 OTUD4 PACSIN1 PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-73O6.3 RP11-848P1.7 RPL10A TP53INP2 TSEN15 UQCC UQCC1 ZBTB38
Waist circumference 3.57 16 11 33.3 0.87 1.5e-06 AC103965.1 ADCY3 C18orf8 C6orf106 CDK6 CTPS1 E2F1 GNA12 NCOA6 NPC1 OTUD4 PACSIN1 RAD9A RP11-848P1.7 RPL10A ZBTB38
Past tobacco smoking 2.10 6 0 0.0 0.50 3.1e-01 C18orf8 GGT7 MAP1LC3A NCOA6 RP11-977G19.11 TMEM180
Nervous feelings 1.60 2 0 0.0 0.00 1.0e+00 CENPW DOPEY1
Hearing difficulty/problems with background noise 1.33 2 0 0.0 0.00 1.0e+00 LIN28B TMEM180
Hair/balding pattern: Pattern 2 1.33 1 0 0.0 0.00 1.0e+00 CENPW
Had menopause 1.20 1 0 0.0 0.00 1.0e+00 RP11-73O6.3
Forced vital capacity (FVC) 11.17 46 38 115.2 0.94 1.3e-23 AC103965.1 ADCY3 BCS1L C6orf106 CD79B CDK6 CDKN2C CENPW CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DLEU2 DYM E2F1 EBPL EFEMP1 GDF5 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 MAPK9 MRPL42 MST1L NOSTRIN OTUD4 PACSIN1 PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-977G19.11 RPL10A TMEM180 TP53INP2 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Heel bone mineral density (BMD) T-score, automated (right) 2.53 10 1 3.0 -0.45 2.0e-01 CDK6 CHRNB1 CTPS1 DEF6 DLEU2 DOPEY1 EBPL NCOA6 RP11-435O5.5 ZBTB38
Qualifications: None of the above 1.60 2 0 0.0 0.00 1.0e+00 CENPW UQCC1
Allergy 2.47 6 4 12.1 0.18 6.5e-01 C6orf106 GNA12 P4HA2 SEMA3B-AS1 TMEM180 ZBTB38
Diabetes (self-reported) 1.45 3 0 0.0 0.00 1.0e+00 AKR1C3 CENPW SEC16A
Medication: Ramipril 1.30 1 0 0.0 0.00 1.0e+00 C6orf106
Fluid intelligence score 1.38 2 0 0.0 0.00 1.0e+00 DCAF16 RP11-435O5.5
Weight 11.06 51 42 127.3 0.95 1.0e-28 AC103965.1 C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CNIH4 CRLF3 CTD-3076O17.1 CTPS1 DCAF16 DDX42 DIS3L2 DLEU1 DLEU2 E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC MAP1LC3A MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38
Impedance of arm (right) 3.46 23 13 39.4 -0.05 8.3e-01 AC103965.1 C18orf8 C6orf106 CD79B CENPW CTD-3076O17.1 DLEU1 E2F1 EFEMP1 GDF5 GPR126 LIN28B LOXL1-AS1 LTBP1 MAP1LC3A MRPL42 MST1L NCOA6 PACSIN1 PHF20 RP11-196G18.22 RP11-529H20.5 RP11-73O6.3
Arm fat percentage (right) 2.12 10 6 18.2 -0.08 8.1e-01 ADCY3 C18orf8 C6orf106 CD79B CENPW DCAF16 DDX42 GNA12 RP11-196G18.22 ZNF76
Trunk fat-free mass 20.05 65 62 187.9 0.96 5.8e-39 ADCY3 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DOPEY1 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 MST1L NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Hip circumference 7.55 38 31 93.9 0.92 2.3e-18 AC103965.1 ADCY3 C18orf8 C6orf106 CD79B CDK6 CDKN2C CRLF3 CTPS1 DLEU1 DLEU2 E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 MAP1LC3A NCOA6 NOSTRIN NPC1 OTUD4 PACSIN1 PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RPL10A TP53INP2 TSEN15 UQCC UQCC1 ZBTB38
Worrier / anxious feelings 1.24 1 0 0.0 0.00 1.0e+00 TMEM180
Frequency of tiredness / lethargy in last 2 weeks 1.58 1 0 0.0 0.00 1.0e+00 NCOA6
Hair/balding pattern: Pattern 3 1.97 2 1 3.0 0.00 1.0e+00 CENPW MAP1LC3A
Forced expiratory volume in 1-second (FEV1) 9.60 44 34 103.0 0.94 6.9e-23 AC103965.1 ADCY3 BCS1L C6orf106 CD79B CDK6 CDKN2C CENPW CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DLEU2 E2F1 EBPL EFEMP1 GDF5 GGT7 GSDMC JMJD4 LOXL1-AS1 MAPK9 MRPL42 MST1L NOSTRIN OTUD4 P4HA2 PACSIN1 PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-977G19.11 RPL10A TMEM180 TP53INP2 UQCC ZBTB38 ZHX2 ZNF76
Pulse rate 1.23 1 1 3.0 0.00 1.0e+00 ZBTB38
Qualifications: A levels/AS levels or equivalent 1.77 4 0 0.0 0.99 9.4e-03 DCAF16 GDF5 UQCC UQCC1
Asthma 2.06 2 2 6.1 0.00 1.0e+00 P4HA2 ZNF76
Illnesses of mother 1.45 1 0 0.0 0.00 1.0e+00 DCAF16
Forced expiratory volume in 1-second (FEV1), Best measure 9.78 45 33 100.0 0.95 1.7e-23 AC103965.1 ADCY3 BCS1L C6orf106 C6orf81 CD79B CDK6 CDKN2C CENPW CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU2 E2F1 EBPL EFEMP1 GDF5 GGT7 GSDMC JMJD4 LOXL1-AS1 MAPK9 MMP24 MRPL42 MST1L NOSTRIN OTUD4 P4HA2 PACSIN1 PHF20 RAB24 RAD9A RP11-361D14.2 RP11-73O6.3 RP11-977G19.11 RPL10A TMEM180 TP53INP2 UQCC ZBTB38 ZHX2 ZNF76
Impedance of arm (left) 3.54 25 13 39.4 0.05 8.0e-01 AC103965.1 C18orf8 C6orf106 CD79B CENPW CTD-3076O17.1 DLEU1 E2F1 EFEMP1 GDF5 GNA12 GPR126 LIN28B LOXL1-AS1 LTBP1 MAP1LC3A MRPL42 MST1L NCOA6 PACSIN1 PHF20 RAD9A RP11-196G18.22 RP11-529H20.5 RP11-73O6.3
Arm fat mass (right) 3.56 20 13 39.4 0.84 5.2e-07 ADCY3 C18orf8 C6orf106 CDK6 DLEU1 E2F1 GGT7 GNA12 NCOA6 NPC1 OTUD4 PACSIN1 PHF20 RAD9A RP11-196G18.22 RP11-73O6.3 RPL10A TP53INP2 UQCC ZBTB38
Trunk predicted mass 20.02 64 62 187.9 0.96 6.8e-39 ADCY3 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 MST1L NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Standing height 26.22 73 73 221.2 0.98 6.1e-53 AC103965.1 ADCY3 AKR1C3 BCS1L C18orf8 C6orf106 C6orf81 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DOPEY1 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LIN28B LOXL1-AS1 LTBP1 MAP1LC3A MAPK9 MMP24 MRPL42 MST1L NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A SEMA3B-AS1 TMEM180 TOP3A TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Tense / 'highly strung' 1.23 2 0 0.0 0.00 1.0e+00 CNIH4 RP11-196G18.22
Hair/balding pattern: Pattern 4 2.16 4 2 6.1 -0.71 2.9e-01 CDKN2C CENPW NCOA6 ZBTB38
Birth weight of first child 2.62 7 3 9.1 0.98 2.7e-05 DCAF16 OTUD4 RP11-361D14.2 RP11-73O6.3 RPL10A ZBTB38 ZNF76
Peak expiratory flow (PEF) 7.38 30 16 48.5 0.96 8.0e-19 ADCY3 C6orf106 CD79B CDKN2C DCAF16 DLEU2 EBPL EFEMP1 FAM83C GDF5 GGT7 GSDMC LOXL1-AS1 MAP1LC3A MMP24 NCOA6 NOSTRIN OTUD4 P4HA2 PHF20 RAD9A RP11-361D14.2 RP11-73O6.3 RPL10A TMEM180 TP53INP2 UQCC UQCC1 ZHX2 ZNF76
Blood clot in the leg (DVT) 1.91 3 0 0.0 0.00 1.0e+00 E2F1 MAP1LC3A PHF20
Hypothyroidism/myxoedema (self-reported) 0.89 2 0 0.0 0.00 1.0e+00 DEF6 DLEU1
Birth weight 3.63 13 4 12.1 0.87 9.9e-05 CDK6 CENPW CRLF3 DCAF16 DEF6 DIS3L2 GNA12 GPR126 RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 SEC16A ZNF76
Forced vital capacity (FVC), Best measure 11.27 51 40 121.2 0.94 4.9e-26 AC103965.1 ADCY3 BCS1L C6orf106 CD79B CDK6 CDKN2C CENPW CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 MAPK9 MMP24 MRPL42 MST1L NOSTRIN OTUD4 PACSIN1 PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-977G19.11 RPL10A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Body fat percentage 2.51 14 8 24.2 0.28 3.0e-01 AC103965.1 ADCY3 C18orf8 C6orf106 CD79B CENPW CTD-3076O17.1 DCAF16 DDX42 GNA12 PACSIN1 RP11-196G18.22 ZBTB38 ZNF76
Leg fat percentage (right) 2.56 13 9 27.3 -0.35 2.1e-01 AC103965.1 ADCY3 C18orf8 C6orf106 CD79B CENPW DCAF16 DDX42 GDF5 MMP24 PHF20 RP11-435O5.5 UQCC
Arm fat-free mass (right) 17.18 60 57 172.7 0.96 1.0e-36 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Comparative body size at age 10 3.13 5 2 6.1 -0.65 2.4e-01 ADCY3 C18orf8 C6orf81 LIN28B RP11-529H20.5
Number of children fathered 1.14 1 0 0.0 0.00 1.0e+00 RP11-977G19.11
Age at first live birth 1.16 1 0 0.0 0.00 1.0e+00 DCAF16
Shortness of breath walking on level ground 1.55 1 0 0.0 0.00 1.0e+00 C18orf8
Qualifications: College or University degree 1.55 9 2 6.1 0.75 2.0e-02 C18orf8 CENPW DCAF16 DDX42 FAM83C GDF5 MAP1LC3A UQCC UQCC1
Mouth/teeth dental problems: Loose teeth 1.32 1 1 3.0 0.00 1.0e+00 CCDC91
Medication for pain relief, constipation, heartburn 1.74 1 0 0.0 0.00 1.0e+00 C6orf106
Angina (self-reported) 2.00 1 0 0.0 0.00 1.0e+00 NCOA6
Medication: Seretide 50 evohaler 1.12 1 0 0.0 0.00 1.0e+00 P4HA2
Mean time to correctly identify matches 1.22 1 0 0.0 0.00 1.0e+00 RP11-73O6.3
Whole body fat mass 4.83 27 19 57.6 0.89 5.4e-11 AC103965.1 ADCY3 C18orf8 C6orf106 CDK6 CTD-3076O17.1 DLEU1 E2F1 EFEMP1 GDF5 GGT7 GNA12 GPR126 NCOA6 NPC1 OTUD4 PACSIN1 PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-73O6.3 RPL10A TP53INP2 UQCC UQCC1 ZBTB38
Leg fat mass (right) 3.54 15 12 36.4 0.83 1.6e-05 AC103965.1 ADCY3 C18orf8 C6orf106 CDK6 E2F1 GNA12 NCOA6 NPC1 OTUD4 PACSIN1 RAD9A RP11-73O6.3 RPL10A ZBTB38
Arm predicted mass (right) 17.00 60 56 169.7 0.96 1.8e-36 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Pulse rate, automated reading 1.48 3 2 6.1 -0.13 8.3e-01 C6orf106 FAM83C ZBTB38
Alcohol intake frequency. 1.26 2 2 6.1 0.00 1.0e+00 C18orf8 TOP3A
Comparative height size at age 10 21.17 69 64 193.9 0.97 3.2e-43 AC103965.1 ADCY3 BCS1L C18orf8 C6orf106 C6orf81 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTD-3076O17.1 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LOXL1-AS1 LTBP1 MAP1LC3A MAPK9 MMP24 MRPL42 MST1L NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TOP3A TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Overall health rating 1.60 4 1 3.0 0.32 5.3e-01 C18orf8 C6orf106 DCAF16 LOXL1-AS1
Family relationship satisfaction 1.14 1 0 0.0 0.00 1.0e+00 RP11-73O6.3
Knee pain experienced in last month 2.80 4 2 6.1 -0.99 9.6e-03 FAM83C GDF5 PHF20 UQCC
Hypertension (Self-reported) 1.33 3 1 3.0 0.00 1.0e+00 C6orf106 DCAF16 P4HA2
Smoking status: Previous 1.98 1 0 0.0 0.00 1.0e+00 C18orf8
Whole body fat-free mass 18.29 62 61 184.8 0.96 5.7e-37 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Leg fat-free mass (right) 15.04 62 47 142.4 0.95 3.1e-34 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LIN28B LOXL1-AS1 MAP1LC3A MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Arm fat percentage (left) 2.19 10 6 18.2 -0.05 8.7e-01 ADCY3 C18orf8 C6orf106 CD79B CENPW DCAF16 DDX42 GNA12 RP11-196G18.22 ZNF76
Average weekly red wine intake 1.82 1 1 3.0 0.00 1.0e+00 C18orf8
Loneliness, isolation 1.23 1 0 0.0 0.00 1.0e+00 C6orf81
Diabetes diagnosed by doctor 1.57 1 0 0.0 0.00 1.0e+00 CENPW
Friendships satisfaction 0.73 1 0 0.0 0.00 1.0e+00 C18orf8
Medication for cholesterol 1.79 1 0 0.0 0.00 1.0e+00 C6orf106
Back pain experienced in last month 1.71 1 0 0.0 0.00 1.0e+00 C6orf106
Breast cancer (self-reported) 1.35 1 0 0.0 0.00 1.0e+00 CDKN2C
Asthma (self-reported) 1.99 4 2 6.1 0.92 8.5e-02 DEF6 P4HA2 ZBTB38 ZNF76
Forced expiratory volume in 1-second (FEV1), predicted percentage 2.65 6 2 6.1 -0.02 9.7e-01 CCDC91 GPR126 RP11-361D14.2 RPL10A UQCC ZNF76
Whole body water mass 18.04 62 59 178.8 0.96 7.9e-37 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Leg predicted mass (right) 15.05 62 47 142.4 0.95 4.3e-34 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 KDM5A LIN28B LOXL1-AS1 MAP1LC3A MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Arm fat mass (left) 3.73 21 13 39.4 0.84 2.5e-07 ADCY3 C18orf8 C6orf106 CDK6 DLEU1 E2F1 GDF5 GGT7 GNA12 NCOA6 NPC1 OTUD4 PACSIN1 PHF20 RAD9A RP11-196G18.22 RP11-73O6.3 RPL10A TP53INP2 UQCC ZBTB38
Number of self-reported non-cancer illnesses 1.41 1 0 0.0 0.00 1.0e+00 P4HA2
Miserableness 0.98 1 0 0.0 0.00 1.0e+00 LOXL1-AS1
Guilty feelings 1.22 1 1 3.0 0.00 1.0e+00 LIN28B
Commuting to job workplace: Public transport 1.01 1 0 0.0 0.00 1.0e+00 SEMA3B-AS1
Medication: Blood pressure 1.56 2 2 6.1 0.00 1.0e+00 C6orf106 P4HA2
High cholesterol (Self-reported) 1.67 1 0 0.0 0.00 1.0e+00 DCAF16
Medication: Bendroflumethiazide 1.17 1 0 0.0 0.00 1.0e+00 P4HA2
Ever smoked 1.42 1 0 0.0 0.00 1.0e+00 TMEM180
Basal metabolic rate 16.93 63 57 172.7 0.95 1.8e-36 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LIN28B LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-196G18.22 RP11-361D14.2 RP11-435O5.5 RP11-529H20.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Leg fat percentage (left) 2.52 14 8 24.2 -0.37 1.6e-01 AC103965.1 ADCY3 C18orf8 C6orf106 CD79B CENPW DCAF16 DDX42 GDF5 MMP24 P4HA2 RP11-435O5.5 UQCC ZNF76
Arm fat-free mass (left) 16.71 60 56 169.7 0.96 2.9e-36 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76
Number of operations (self-reported) 1.93 2 0 0.0 0.00 1.0e+00 GNA12 LIN28B
Irritability 1.32 2 0 0.0 0.00 1.0e+00 MAP1LC3A RP11-73O6.3
Ever had prostate specific antigen (PSA) test 1.57 1 0 0.0 0.00 1.0e+00 ZBTB38
Diastolic blood pressure, automated reading 1.37 4 1 3.0 -0.67 3.3e-01 ADCY3 DCAF16 P4HA2 ZNF76
Myopia 1.70 1 0 0.0 0.00 1.0e+00 C6orf106
Vascular/heart problems diagnosed by doctor 1.43 3 2 6.1 0.00 1.0e+00 C6orf106 DCAF16 P4HA2
Cholesterol lowering medication 1.70 1 0 0.0 0.00 1.0e+00 DDX42
Pain experienced in last month 1.55 1 0 0.0 0.00 1.0e+00 CENPW
Deep venous thrombosis (DVT) (self-reported) 1.93 3 0 0.0 0.00 1.0e+00 E2F1 MAP1LC3A PHF20
Heart disease (siblings) 2.03 1 0 0.0 0.00 1.0e+00 TP53INP2
Impedance of whole body 3.66 28 22 66.7 -0.10 5.9e-01 AC103965.1 ADCY3 C6orf106 CD79B CENPW CTD-3076O17.1 DLEU1 E2F1 EFEMP1 FAM83C GDF5 GPR126 LIN28B LTBP1 MAP1LC3A MRPL42 MST1L NCOA6 OTUD4 PACSIN1 PHF20 RAB24 RAD9A RP11-196G18.22 RP11-73O6.3 SEMA3B-AS1 TOP3A UQCC
Leg fat mass (left) 3.56 15 11 33.3 0.84 1.6e-05 AC103965.1 ADCY3 C18orf8 C6orf106 CDK6 E2F1 GNA12 NCOA6 NPC1 OTUD4 PACSIN1 RAD9A RP11-73O6.3 RPL10A ZBTB38
Arm predicted mass (left) 16.59 60 56 169.7 0.96 6.1e-36 AKR1C3 BCS1L C18orf8 C6orf106 CCDC91 CD79B CDK6 CDKN2C CENPW CHRNB1 CNIH4 CRLF3 CTPS1 DCAF16 DDX42 DEF6 DIS3L2 DLEU1 DLEU2 DYM E2F1 EBPL EFEMP1 FAM83C GDF5 GGT7 GNA12 GPR126 GSDMC JMJD4 LOXL1-AS1 MAP1LC3A MAPK9 MMP24 MRPL42 NCOA6 NOSTRIN NPC1 OTUD4 P4HA2 PACSIN1 PDE6D PHF20 RAB24 RAD9A RP11-361D14.2 RP11-435O5.5 RP11-73O6.3 RP11-848P1.7 RP11-977G19.11 RPL10A SEC16A TMEM180 TP53INP2 TSEN15 UQCC UQCC1 ZBTB38 ZHX2 ZNF76

Associations by panel

study tissue # hits % hits/tests avg chisq
GTEx Adipose Subcutaneous 22 0.630 2.27
GTEx Adipose Visceral Omentum 10 0.491 2.22
GTEx Adrenal Gland 7 0.480 2.13
GTEx Artery Aorta 16 0.537 2.24
GTEx Artery Coronary 4 0.338 2.06
GTEx Artery Tibial 28 0.744 2.33
GTEx Brain Caudate basal ganglia 2 0.217 1.96
GTEx Brain Cerebellar Hemisphere 6 0.403 2.07
GTEx Brain Cerebellum 10 0.505 2.15
GTEx Brain Cortex 6 0.580 2.30
GTEx Brain Frontal Cortex BA9 4 0.433 2.15
GTEx Brain Hippocampus 2 0.382 2.34
GTEx Brain Hypothalamus 5 0.847 2.17
GTEx Brain Nucleus accumbens basal ganglia 6 0.694 2.17
GTEx Brain Putamen basal ganglia 4 0.641 2.10
GTEx Breast Mammary Tissue 11 0.557 2.11
GTEx Breast Mammary Tissue (Male) 12 1.006 2.32
GTEx Breast Mammary Tissue (Female) 7 0.426 2.10
GTEx Cells EBV-transformed lymphocytes 11 0.773 2.20
GTEx Cells Transformed fibroblasts 17 0.405 2.10
GTEx Colon Sigmoid 5 0.342 2.17
GTEx Colon Transverse 13 0.630 2.25
GTEx Esophagus Gastroesophageal Junction 7 0.484 2.12
GTEx Esophagus Mucosa 27 0.813 2.21
GTEx Esophagus Muscularis 18 0.557 2.18
GTEx Heart Atrial Appendage 12 0.760 2.16
GTEx Heart Left Ventricle 5 0.327 2.00
GTEx Liver 3 0.418 2.09
GTEx Lung 17 0.592 2.18
GTEx Muscle Skeletal 17 0.588 2.24
GTEx Nerve Tibial 29 0.671 2.17
GTEx Ovary 5 0.551 2.27
GTEx Pancreas 12 0.735 2.21
GTEx Pituitary 10 0.897 2.30
GTEx Prostate 2 0.240 2.14
GTEx Skin Not Sun Exposed Suprapubic 15 0.610 2.10
GTEx Skin Sun Exposed Lower leg 21 0.577 2.25
GTEx Small Intestine Terminal Ileum 2 0.434 2.15
GTEx Spleen 7 0.496 2.20
GTEx Stomach 12 0.825 2.15
GTEx Testis 21 0.666 2.32
GTEx Thyroid 24 0.600 2.15
GTEx Uterus 0 0.000 1.96
GTEx Vagina 1 0.157 1.81
GTEx Whole Blood 9 0.452 2.16
METSIM Adipose 17 0.369 1.98
NTR Blood 10 0.416 2.01
ROSMAP Brain Pre-frontal Cortex 19 0.433 2.09
YFS Blood 19 0.411 1.94
CommonMind Brain Pre-frontal Cortex 23 0.428 2.00
TCGA Breast Tumor 4 0.522 2.05
TCGA Breast Normal 18 0.428 1.93
TCGA Ovarian Tumor 11 0.376 1.78
TCGA Prostate Tumor 16 0.463 2.03